budesonide (MAP0010) / AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide (MAP0010) / AbbVie
UDB P101, NCT00627679: Safety and Blood Level Study of Unit Dose Budesonide

Completed
1
16
RoW
Budesonide Inhalation Suspension, Pulmicort Respules®, MAP0010 low dose, MAP0010 intermediate dose, MAP0010 high dose
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty Limited
Asthma
12/05
05/06

Download Options